Next Article in Journal
Effective Dose Reduction of Emamectin Benzoate Through Inhibition of Bx-SDR3 in Pine Wood Nematode Management
Next Article in Special Issue
Exploring the Potential Roles of SLC39A8 and POC5 Missense Variants in the Association Between Body Composition, Beverage Consumption, and Chronic Lung Diseases: A Two-Sample Mendelian Randomization Study
Previous Article in Journal
Correlations Between Amelioration of Rotenone-Induced Parkinson’s Symptoms by Amomum tsaoko Flavonoids and Gut Microbiota in Mice
Previous Article in Special Issue
Pathogenetic Mechanisms Linking Sarcoidosis to Lymphoma
 
 
Review
Peer-Review Record

Exploring Asthma as a Protective Factor in COVID-19 Outcomes

Int. J. Mol. Sci. 2025, 26(4), 1678; https://doi.org/10.3390/ijms26041678
by Anthony E. Quinn 1,†, Lei Zhao 2,†, Scott D. Bell 1, Muhammad H. Huq 1 and Yujiang Fang 1,3,4,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2025, 26(4), 1678; https://doi.org/10.3390/ijms26041678
Submission received: 19 January 2025 / Revised: 13 February 2025 / Accepted: 14 February 2025 / Published: 16 February 2025
(This article belongs to the Special Issue Molecular Pathophysiology of Lung Diseases)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

The work of Quinn et al. is a mini review that Explores asthma as a protective factor in COVID-19 outcomes. The Ms is clearly written, concise with appropriate considerations on the possible protective mechanisms that asthmatic patients might display that make them more resistant to COVID-19. The work might be of interest for the broad readership of Int. J. Mol. Sci.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

The review is based on a current topic, using new research findings. The review analyzes the impact of asthma on patients infected with SARS-CoV-2 and the risk of severe infection. It provides data on the overall protective effect against SARS-CoV-2 infection through various mechanisms, including eosinophilia, inhaled steroid use, reduced ACE expression, and the dominance of type 2 inflammation in asthma.

I missed several important questions that would be of interest to readers: the effect of SARS-CoV-2 vaccines and biologics on the severity of COVID-2019 in asthma. It would be desirable to supplement the review in these aspects.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop